Page 1

COAC Immune PRESS RELEASE AC Immune First Half 2026 Financial and Corporate Update Focused portfolio of wholly - owned programs approach near - term clinical catalysts as partnered programs generate milestone payments • • • • Key advances across pipeline , with further near - term clinical results anticipated for H2 2026 Phase 2 VacSYn trial of ACI - 7104 in Parkinson's disease supported by a $ 4 million grant from The Vijay and Marie Goradia Charitable Foundation Morphomer small molecule program targeting intracellular Tau progresses with Lilly Initiation of Alzheimer's disease AD4 cohort in ABATE trial triggered $ 12 million milestone payment from Takeda Cash resources of CHF 75.4 million as of June 30 , 2026 , provide funding into Q4 2027 Lausanne , Switzerland , August 5 , 2026 AC Immune SA ( NASDAQ : ACIU ) , a clinical - stage biopharmaceutical company developing targeted therapeutics for neurodegenerative diseases , today provided a corporate and financial update for the half - year ended June 30 , 2026 . Martin Zügel , MD , interim CEO of AC Immune and Chair of the Board of Directors , commented : " AC Immune is moving towards key clinical milestones in two of our wholly - owned programs , a growing focus for AC Immune . These data include full results from Part 1 of the VacSYn trial of ACI- 7104 , our anti - a - syn active immunotherapy in Parkinson's disease , as well as initial data from our ACI - 19764 trial . The important milestone payments in our partnered programs ensure we are funded into Q4 2027 , and that we are well - positioned as we approach these near - term clinical results . " First Half 2026 and Subsequent Highlights : Wholly - Owned Programs AC Immune's wholly - owned pipeline is built around three differentiated programs against a - synuclein , TDP - 43 , and NLRP3 , targeting key mechanisms underlying neurodegenerative disease based on extensive preclinical data . The following updates focus on our clinical stage programs . ACI - 7104 is an active immunotherapy targeting pathological a - synuclein in Parkinson's disease , designed to generate a targeted immune response with the potential to modify disease progression . ACI - 19764 is a small- molecule NLRP3 inflammasome inhibitor aimed at reducing neuroinflammation , a fundamental driver of multiple neurodegenerative disorders . ACI - 19626 is a first - in - class TDP - 43 PET tracer designed to visualize TDP - 43 pathology in living patients , addressing a major unmet need in ALS and related diseases . Together , these assets provide multiple near - term data catalysts and showcase AC Immune's ability to translate deep neuroscience expertise into both therapeutics and diagnostics . ACI - 7104 : anti - a - syn active immunotherapy